<DOC>
	<DOCNO>NCT01138267</DOCNO>
	<brief_summary>Objectives : - To evaluate impact genetic polymorphism ARV drug level - To evaluate effect genetic polymorphism/drug level long term immunologic virologic response - To correlate genetic polymorphism/drug level antiretroviral toxicity The long-term objective research plan characterize impact pharmacogenomics HIV drug concentration , toxicity , response antiretroviral therapy among HIV-infected adult . A comprehensive understanding impact pharmacogenomics HIV infection HIV medication lead development appropriate intervention dose reduction strategy patient particular gene ( ) correlate high drug level . The dose reduction strategy decrease long term drug toxicity cost save Thais Asian Ethnicities .</brief_summary>
	<brief_title>Pharmacogenomic Atazanavir/Efavirenz ( ATV/EFV )</brief_title>
	<detailed_description>The overall goal study characterize role pharmacogenomic ARV drug ( atazanavir , efavirenz ) level , toxicity , long term efficacy among HIV-infected adult Thailand . The specific aim ( 1 ) evaluate impact genetic polymorphism ARV drug level ( 2 ) evaluate effect genetic polymorphism/ drug level long term immunologic virologic response ( 3 ) correlate genetic polymorphism/drug level antiretroviral toxicity . The propose study analyse stored sample well-established cohort long-term follow-up study HIV-infected patient participate HIV-NAT study protocol , HIV-NAT006 study . This cohort provide u unique opportunity study impact pharmacogenomics long term treatment response long term drug toxicity since cohort start 1996 . Furthermore , important factor include ARV regimen , drug toxicity , PBMC , immunological virological parameter collect every 6 month basis HIV-NAT006 study . A comprehensive understanding impact pharmacogenomics HIV infection HIV medication lead development appropriate intervention , particularly , dose reduction strategy patient particular gene correlate great drug level . The dose reduction strategy decrease long term drug toxicity cost save Thai Asian Ethnicity .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Inclusion criterion pharmacogenomic ATV : 1 . On lowdose ATV/r time blood sample collect ATV drug level 2 . Age &gt; 18 year age old HIV1 infection 3 . Provided consent form Inclusion criterion pharmacogenomic EFV : On EFV time blood sample collect EFV level Age &gt; 18 year age old HIV1 infection Patients EFV later switch another ARV regimen due toxicity EFV store sample time take EFV Provided consent form Exclusion criterion ATV EFV 1 . Inability understand nature extent study procedure require . 2 . Contramedication rifampin , proton pump inhibitor ( ATV ) , etc 3 . Pregnancy blood drawn EFV ATV drug level 4 . Known renal insufficiency cirrhosis blood drawn EFV ATV drug level</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>pharmacogenomics</keyword>
	<keyword>ATV</keyword>
	<keyword>EFV</keyword>
	<keyword>pharmacogenomics ATV EFV</keyword>
</DOC>